litlas
Log inCreate account

Nicolas Penel

Active 2001–2025

164
Papers
20,272
Citations
77
h-index
160
i10-index

Citations

Citations per year for Nicolas Penel1996: 2 citations2004: 2 citations2005: 1 citations2006: 1 citations2007: 5 citations2008: 6 citations2009: 2 citations2010: 18 citations2011: 14 citations2012: 27 citations2013: 40 citations2014: 68 citations2015: 67 citations2016: 79 citations2017: 100 citations2018: 89 citations2019: 407 citations2020: 864 citations2021: 1,040 citations2022: 900 citations2023: 713 citations2024: 1,222 citations2025: 589 citations2026: 9 citations1997–2003: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,844 citing papers, 20.8% of this breakdownChina: 951 citing papers, 10.8% of this breakdownItaly: 695 citing papers, 7.9% of this breakdownFrance: 663 citing papers, 7.5% of this breakdownUnited Kingdom: 514 citing papers, 5.8% of this breakdownGermany: 473 citing papers, 5.3% of this breakdownSpain: 351 citing papers, 4% of this breakdownNetherlands: 317 citing papers, 3.6% of this breakdownJapan: 316 citing papers, 3.6% of this breakdownCanada: 271 citing papers, 3.1% of this breakdownSwitzerland: 194 citing papers, 2.2% of this breakdownAustralia: 181 citing papers, 2% of this breakdown
0%20.8%Other 23.4%

Institutions

Fields

  • Medicine83%
  • Biochemistry, Genetics and Molecular Biology11.4%
  • Immunology and Microbiology3.1%
  • Neuroscience0.4%
  • Health Professions0.4%
  • Engineering0.4%
  • Other1.3%

Topics

  • Sarcoma Diagnosis and Treatment8.4%
  • Cancer Immunotherapy and Biomarkers7.7%
  • Cancer Genomics and Diagnostics3%
  • Vascular Tumors and Angiosarcomas2.6%
  • Pancreatic and Hepatic Oncology Research2.4%
  • Immunotherapy and Immune Responses2.4%
  • Other73.5%

Coauthors

All papers

Open in search
  1. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

    Authors: Aurélien Marabelle, Dung T. Le, Paolo A. Ascierto, Anna Maria Di Giacomo, Ana De Jesus‐Acosta, Jean-Pierre Delord, Ravit Geva, Maya Gottfried, Nicolas Penel, Aaron R. Hansen, Sarina A. Piha‐Paul, Toshihiko Doi, Bo Gao, Hyun Cheol Chung, José A. López-Martín, Yung-Jue Bang, Ronnie Shapira Frommer, Manisha H. Shah, Razi Ghori, Andrew K. Joe, Scott K. Pruitt, Luis A. Díaz - Journal of Clinical Oncology 2019 cited by 2,963

  2. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study

    Authors: Michele Maio, Paolo A. Ascierto, L. V. Manzyuk, Daniel Motola‐Kuba, Nicolas Penel, Philippe A. Cassier, Giovanni M. Bariani, A. De Jesus Acosta, Toshihiko Doi, Federico Longo, Wilson H. Miller, Do‐Youn Oh, Maya Gottfried, Lei Xu, Fan Jin, Kevin Norwood, Aurélien Marabelle - Annals of Oncology 2022 cited by 445

  3. Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort

    Authors: Antoîne Italiano, Alban Bessede, M. Pulido, Emmanuelle Bompas, Sophie Piperno‐Neumann, Christine Chevreau, Nicolas Penel, François Bertucci, Maud Toulmonde, Carine Bellera, Jean‐Philippe Guégan, Christophe Rey, Catherine Sautès‐Fridman, Antoine Bougoüin, Coralie Cantarel, Michèle Kind, M. Spalato, Bérengère Dadone‐Montaudié, François Le Loarer, Jean‐Yves Blay, Wolf H. Fridman - Nature Medicine 2022 cited by 263

  4. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study

    Authors: Shubham Pant, Martin Schüler, Gopa Iyer, Olaf Witt, Toshihiko Doi, Toshihiko Doi, Josep Tabernero, David A. Reardon, Christophe Massard, Anna Minchom, Iwona Ługowska, Omar Carranza, Dirk Arnold, Martin Gutierrez, Helen Winter, Kim Stuyckens, Lauren Crow, Saltanat Najmi, Constance Hammond, Shibu Thomas, Ademi Santiago-Walker, Spyros Triantos, Hussein Sweiti, Yohann Loriot, Omar Carranza, Martin Alberto Greco, Omar Carranza, Anthony M. Joshua, Christos S. Karapetis, Christopher D. Hart, Alison Y. Zhang, Hans Prenen, Jean‐Charles Goeminne, Jean‐Pascal Machiels, Sylvie Rottey, Marcelo Corassa, Graziela Zibetti Dal Molin, Katsuki Arima Tiscoski, Denis L. Jardim, Milena Perez Mak, Wei Fu, Herui Yao, Jing Huang, Haiping Jiang, Jing Huang, Baoshi Chen, Dong Yan, Yu Yang, Yohann Loriot, Christophe Le Tourneau, Nicolas Penel, Sébastien Salas, Jean‐Yves Blay, Pierre-Emmanuel Brachet, Xavier Durando, Sheik Emambux, Alain Ravaud, Gunnar Folprecht, Dirk Arnold, Martin Schüler, Marit Ahrens, Alexander Golf, Georg Martin Haag, Florian Lordick, Alexander Desuki, Marina Elena Cazzaniga, Fortunato Ciardiello, Michèle Milella, Takafumi Koyama, Yoshiki Hirooka, Wataru Okamoto, Kenjiro Aogi, Yasutoshi Kuboki, Jung-Yun Lee, Sung‐Bae Kim, Myung‐Ju Ahn, Jong Hee Chang, Yongman Kim, Do‐Hyun Nam, Jaesung Park, Iwona Ługowska, Luis Paz‐Ares, Víctor Moreno, Andrés Cervantes, Mariona Calvo, Alejandro Falcón, Antonio González, Josep Tabernero, A. Martinez Bueno, Javier García-Corbacho, Federico Longo, Chia‐Jui Yen, Jen‐Shi Chen, Ming‐Feng Hou, Yee Chao, Kun‐Ming Rau, Tai‐Jan Chiu, Yin‐Hsun Feng, Chih‐Hung Hsu, Wen‐Tsung Huang and 33 more - The Lancet Oncology 2023 cited by 200

  5. Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas

    Authors: Maud Toulmonde, Nicolas Penel, Julien Adam, Christine Chevreau, Jean‐Yves Blay, Axel Le Cesne, Emmanuelle Bompas, Sophie Piperno‐Neumann, Sophie Cousin, Thomas Grellety, Thomas Ryckewaert, Alban Bessede, François Ghiringhelli, Marina Pulido, Antoîne Italiano - JAMA Oncology 2017 cited by 394

  6. Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies

    Authors: Hyun Cheol Chung, Sarina A. Piha‐Paul, José A. López-Martín, Jan H.M. Schellens, Steven Kao, Wilson H. Miller, Jean‐Pierre Delord, Bo Gao, David Planchard, Maya Gottfried, Alona Zer, Shadia I. Jalal, Nicolas Penel, Janice M. Mehnert, Ignacio Matos, Jaafar Bennouna, Dong‐Wan Kim, Lei Xu, Suba Krishnan, Kevin Norwood, Patrick A. Ott - Journal of Thoracic Oncology 2019 cited by 438

  7. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study

    Authors: Leila Khoja, Eshetu G. Atenafu, Stefan Suciu, Serge Leyvraz, Takami Sato, E. Marshall, Ulrich Keilholz, Lisa Zimmer, Sapna P. Patel, Sophie Piperno‐Neumann, Josep M. Piulats, Tero Kivelä, Claudia Pfoehler, Shailender Bhatia, Peter Huppert, L.B.J. van Iersel, I. Jolanda M. de Vries, Nicolas Penel, Thomas J. Vogl, Tina Cheng, Giammaria Fiorentini, F. Mouriaux, Ahmad A. Tarhini, Poulam M. Patel, Richard D. Carvajal, Anthony M. Joshua - Annals of Oncology 2019 cited by 286

  8. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial

    Authors: Antoîne Italiano, Olivier Mir, Simone Mathoulin‐Pélissier, Nicolas Penel, Sophie Piperno‐Neumann, Emmanuelle Bompas, Christine Chevreau, Florence Duffaud, Natacha Entz‐Werlé, Esma Saâda, I. L. Ray-Coquard, Cyril Lervat, Nathalie Gaspar, Perrine Marec‐Bérard, Hélène Pacquement, John Wright, Maud Toulmonde, Alban Bessede, Amandine Crombé, Michèle Kind, Carine Bellera, Jean-Yves Blay - The Lancet Oncology 2020 cited by 322

  9. Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial

    Authors: Patricia Pautier, Antoîne Italiano, Sophie Piperno‐Neumann, Christine Chevreau, Nicolas Penel, Nelly Firmin, Pascaline Boudou‐Rouquette, François Bertucci, Corinne Balleyguier, Valérie Lebrun-Ly, Isabelle Ray‐Coquard, Elsa Kalbacher, A. Bardet, Emmanuelle Bompas, Olivier Collard, Nicolás Isambert, Cécile Guillemet, María Rios, Baptiste Archambaud, Florence Duffaud, Antoîne Italiano, Patricia Pautier, A. Lecesne, Sophie Piperno‐Neumann, Christine Chevreau, Didier Cupissol, Nicolas Penel, Jérôme Alexandre, François Bertucci, Isabelle Ray‐Coquard, Valérie Lebrun-Ly, Elsa Kalbacher, Florence Duffaud, Corinne Delcambre, Emmanuelle Bompas, Olivier Collard, Nicolás Isambert, Cécile Guillemet, P Soulié, María Rios, Esma Saâda-Bouzid - The Lancet Oncology 2022 cited by 125

  10. Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network

    Authors: Gonzague de Pinieux, Marie Karanian, François Le Loarer, Sophie Le Guellec, Sylvie Chabaud, Philippe Terrier, Corinne Bouvier, Maxime Batistella, Agnès Neuville, Y Robin, Jean‐François Emile, Anne Moreau, Fréderique Larousserie, Agnès Leroux, Nathalie Stock, Marick Laé, Françoise Collin, Nicolas Weinbreck, Sébastien Aubert, Florence Mishellany, Céline Charon‐Barra, Sabrina Croce, Laurent Doucet, Isabelle Quintin-Rouet, Marie‐Christine Chateau, Céline Bazille, Isabelle Valo, Bruno Chetaille, Nicolás Ortonne, A. Brouchet, Philippe Rochaix, Anne Demuret, Jean‐Pierre Ghnassia, Lénaïg Mescam, Nicolas Macagno, Isabelle Birtwisle‐Peyrottes, Christophe Delfour, Émilie Angot, Isabelle Pommepuy, Dominique Ranchère, Claire Chemin-Airiau, Myriam Jean‐Denis, Yohan Fayet, Jean-Baptiste Courrèges, Nouria Mesli, Juliane Berchoud, Maud Toulmonde, Antoîne Italiano, Axel Le Cesne, Nicolas Penel, Françoise Ducimetière, F. Gouin, Jean‐Michel Coindre, Jean‐Yves Blay, on behalf of the NetSarc/RePPS/ResSos and French Sarcoma Group- Groupe d’Etude des Tumeurs Osseuses (GSF-GETO) networks - PLoS ONE 2021 cited by 263

  11. First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration

    Authors: Jordi Rodón, Hans Prenen, Adrian G. Sacher, Miguel A. Villalona‐Calero, Nicolas Penel, Aya El Helali, Sylvie Rottey, Noboru Yamamoto, François Ghiringhelli, Matthias Goebeler, Toshihiko Doi, Sophie Postel‐Vinay, C-C Lin, Liu C, C-H Chuang, Kiana Keyvanjah, Torsten Eggert, Bert H. O’Neil - Annals of Oncology 2024 cited by 96

  12. Surgery in reference centers improves survival of sarcoma patients: a nationwide study

    Authors: Jean‐Yves Blay, Charles Honoré, Eberhard Stoeckle, Pierre Méeus, Mehrdad Jafari, F. Gouin, Philippe Anract, Gwénaël Ferron, Alexandre Rochwerger, M. Ropars, Sébastien Carrère, Frédéric Marchal, François Sirveaux, A. Di Marco, Louis‐Romée Le Nail, Jérôme Guiramand, Gualter Vaz, Jean-Christophe Machiavello, O. Marco, Sylvain Causeret, Pierre Gimbergues, F. Fiorenza, L. Chaigneau, F. Guillemin, Jean‐Marc Guilloit, F. Dujardin, Jean‐Philippe Spano, J Ruźić, Audrey Michot, Pauline Soibinet, Emmanuelle Bompas, Christine Chevreau, Florence Duffaud, María Rios, Christophe Perrin, Nelly Firmin, François Bertucci, C. Le Péchoux, François Le Loarer, Olivier Collard, Marie Karanian, Mehdi Brahmi, Armelle Dufresne, Aurélien Dupré, Françoise Ducimetière, Antoine Giraud, David Pérol, Maud Toulmonde, Isabelle Ray‐Coquard, Antoîne Italiano, Axel Le Cesne, Nicolas Penel, Sylvie Bonvalot - Annals of Oncology 2019 cited by 332

  13. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial

    Authors: Roy S. Herbst, Hendrik‐Tobias Arkenau, Rafael Santana-Dávila, Emiliano Calvo, Luis Paz‐Ares, Philippe A. Cassier, Johanna C. Bendell, Nicolas Penel, Matthew Krebs, Juan Martín-Liberal, Nicolás Isambert, A. Segado Soriano, Martin Wermke, Jennifer L. Cultrera, Ling Gao, Ryan C. Widau, Gu Mi, Jin Jin, David Ferry, Charles S. Fuchs, Daniel P. Petrylak, Ian Chau - The Lancet Oncology 2019 cited by 275

  14. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

    Authors: Isabelle Ray‐Coquard, Jean‐Yves Blay, Antoîne Italiano, Axel Le Cesne, Nicolas Penel, Jianguo Zhi, Florian Heil, Ruediger Rueger, Bradford Graves, Meichun Ding, David Geho, Steven A. Middleton, Lyubomir T. Vassilev, Gwen Nichols, Binh Bui - The Lancet Oncology 2012 cited by 563

  15. Improved survival using specialized multidisciplinary board in sarcoma patients

    Authors: Jean‐Yves Blay, Pauline Soibinet, Nicolas Penel, Emmanuelle Bompas, Florence Duffaud, Eberhard Stoeckle, Olivier Mir, Julien Adam, Christine Chevreau, Sylvie Bonvalot, María Rios, Pierre Kerbrat, Didier Cupissol, Philippe Anract, F. Gouin, Jean‐Emmanuel Kurtz, Célèste Lebbé, Nicolás Isambert, François Bertucci, M. Toumonde, A. Thyss, Sophie Piperno‐Neumann, Pascale Dubray‐Longeras, Pierre Méeus, Françoise Ducimetière, Antoine Giraud, Jean‐Michel Coindre, Isabelle Ray‐Coquard, Antoîne Italiano, Axel Le Cesne - Annals of Oncology 2017 cited by 362

  16. FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression

    Authors: Cora N. Sternberg, Daniel P. Petrylak, Joaquim Bellmunt, Hiroyuki Nishiyama, Andrea Necchi, Howard Gurney, Jae‐Lyun Lee, Michiel S. van der Heijden, Eli Rosenbaum, Nicolas Penel, See‐Tong Pang, Jian‐Ri Li, Xavier García del Muro, Florence Joly, Zsuzsanna Pápai, Weichao Bao, Peter Ellinghaus, Chengxing Lu, Mitchell Robert Sierecki, Sabine Coppieters, Keiko Nakajima, Tatiane Cristine Ishida, David I. Quinn - Journal of Clinical Oncology 2022 cited by 94

  17. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study

    Authors: Florence Duffaud, Olivier Mir, Pascaline Boudou‐Rouquette, Sophie Piperno‐Neumann, Nicolas Penel, Emmanuelle Bompas, Corinne Delcambre, Elsa Kalbacher, Antoîne Italiano, Olivier Collard, Christine Chevreau, Esma Saâda, Nicolás Isambert, Jessy Delaye, Camille Schiffler, Corinne Bouvier, Vincent Vidal, Sylvie Chabaud, Jean‐Yves Blay - The Lancet Oncology 2018 cited by 316

  18. Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial

    Authors: Jean‐Yves Blay, Sylvie Chevret, Axel Le Cesne, Mehdi Brahmi, Nicolas Penel, Sophie Cousin, François Bertucci, Emmanuelle Bompas, Thomas Ryckewaert, Pauline Soibinet, Pascaline Boudou‐Rouquette, Esma Saada Bouzid, P Soulié, Thibaud Valentin, Jean‐Pierre Lotz, Diégo Tosi, Zoé Nevière, Mathilde Cancel, Isabelle Ray‐Coquard, Laëtitia Gambotti, Frédéric Legrand, Assia Lamrani-Ghaouti, Clotilde Simon, Caroline Even, Christophe Massard - The Lancet Oncology 2023 cited by 88

  19. Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study

    Authors: Nicolas Penel, Binh Bui, Jacques‐Olivier Bay, Didier Cupissol, Isabelle Ray‐Coquard, Sophie Piperno‐Neumann, Pierre Kerbrat, Charles Fournier, S. Taïeb, Marta Jiménez, Nicolás Isambert, Frédéric Peyrade, Christine Chevreau, Emmanuelle Bompas, Étienne Brain, Jean‐Yves Blay - Journal of Clinical Oncology 2008 cited by 693

  20. The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients

    Authors: Ben Alman, Steven Attia, Christina Baumgarten, Charlotte Benson, Jean‐Yves Blay, Sylvie Bonvalot, Jessica Breuing, Ken Cardona, Paolo G. Casali, Frits van Coevorden, Chiara Colombo, Angelo Paolo Dei Tos, Palma Dileo, Andrea Ferrari, Marco Fiore, Anna Maria Frezza, J. Santiago García, Rebecca A. Gladdy, Mrinal M. Gounder, Alessandro Gronchi, Rick L. Haas, Sam Hackett, Florian Haller, Peter Hohenberger, Olga Husson, Robin L. Jones, Ian Judson, Bernd Kasper, Akira Kawai, Vlada Kogosov, Alex J. Lazar, Robert G. Maki, Tim Mathes, Christina Messiou, Fariba Navid, Yoshihiro Nishida, Elena Palassini, Nicolas Penel, Robert Pollock, Dawid Pieper, Marlene Portnoy, Chandrajit P. Raut, Evelyne Roets, Sergio Sandrucci, Marta Sbaraglia, Silvia Stacchiotti, Katherine A. Thornton, Winette van der Graaf, Kim van der Zande, Winan J. van Houdt, Víctor M. Villalobos, Andrew J. Wagner, Eva Wardelmann, Markus Wartenberg, Sarah Watson, Aaron R. Weiss, Nikolaos Zafiropoulos - European Journal of Cancer 2020 cited by 478

  21. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort

    Authors: Byoung Chul Cho, Amaury Daste, Alain Ravaud, Sébastien Salas, Nicolás Isambert, Edward F. McClay, Ahmad Awada, Christian Borel, Laureen S. Ojalvo, Christoph Helwig, P. Alexander Rolfe, James L. Gulley, Nicolas Penel - Journal for ImmunoTherapy of Cancer 2020 cited by 82

  22. A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04)

    Authors: Karim Fizazi, Aline Maillard, Nicolas Penel, G. Baciarello, Djelila Allouache, Gedske Daugaard, A. van de Wouw, G. Soler, Élodie Vauléon, L. Chaigneau, René A. J. Janssen, F. Losa Gaspà, Rafael Morales‐Barrera, Carmen Balañá, Diégo Tosi, Bruno Chauffert, Claudia Schnabel, Géraldine Martineau, S. Culine, Isabelle Borget - Annals of Oncology 2019 cited by 247

  23. Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study

    Authors: Axel Le Cesne, Perrine Marec‐Bérard, Jean‐Yves Blay, Nathalie Gaspar, François Bertucci, Nicolas Penel, Emmanuelle Bompas, Sophie Cousin, Maud Toulmonde, Alban Bessede, Wolf H. Fridman, Catherine Sautès‐Fridman, Michèle Kind, François Le Loarer, M. Pulido, Antoîne Italiano - European Journal of Cancer 2019 cited by 167

  24. AMG 193, a Clinical Stage MTA-Cooperative PRMT5 Inhibitor, Drives Antitumor Activity Preclinically and in Patients with MTAP-Deleted Cancers

    Authors: Brian Belmontes, Katherine K. Slemmons, Chun Su, Siyuan Liu, Antonia N. Policheni, Jodi Moriguchi, Hong Tan, Fang Xie, Daniel Andrew Aiello, Yajing Yang, Raul Lazaro, Famke Aeffner, Matthew G. Rees, Melissa M. Ronan, Jennifer A. Roth, Mikkel Vestergaard, Sanne Cowland, Jan Andersson, Ian Sarvary, Qing Chen, Pooja Sharma, Patricia López, Nuria Tamayo, Liping H. Pettus, Sudipa Ghimire-Rijal, Susmith Mukund, Jennifer R. Allen, Jason DeVoss, Angela Coxon, Jordi Rodón, François Ghiringhelli, Nicolas Penel, Hans Prenen, Sanne Glad, Chen-Hua Chuang, Kiana Keyvanjah, Danielle M. Townsley, John R. Butler, Matthew P. Bourbeau, Sean Caenepeel, Paul E. Hughes - Cancer Discovery 2024 cited by 70